Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

Hansel, Katharina; Patruno, Cataldo; Antonelli, Elettra; Bello, Giacomo Dal; Napolitano, Maddalena; Fabbrocini, Gabriella; Grieco, Teresa; Pellacani, Giovanni; Fargnoli, Maria Concetta; Esposito, Maria; Piras, Viviana; Zucca, M; Girolomoni, Giampiero; Stingeni, Luca

doi:10.1111/ced.14862

Cited by 25 publications

(27 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Again, only one case of COVID-19 at week-10 was mentioned, and this is supposed to be the same reported in the previous article. 43 …”

Section: Dupilumabmentioning

confidence: 99%

“…Again, only one case of COVID-19 at week-10 was mentioned, and this is supposed to be the same reported in the previous article. 43 Finally, a mild course has been recently observed in three COVID-19 cases from Poland reported by Ceryn et al (online publication: August 2021) among their young adults affected with AD and treated with dupilumab. All these three patients were young (27,19 and 17 years old).…”

mentioning

confidence: 91%

See 1 more Smart Citation

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Poddighe¹,

Kovzel²

2021

JIR

View full text Add to dashboard Cite

SARS-CoV-2 pandemic had a general and deep impact on the clinical management of chronic diseases, including respiratory and allergic disorders. At the beginning of the pandemic, one of the main concerns was the potential impact of immunosuppressive/immunomodulatory drugs on COVID-19 clinical course. In this review, we aim to summarize and analyze the available clinical evidence from patients treated with anti-type 2 inflammation biologics (including anti-IgE, anti-IL-5 and anti-IL-4 agents), who developed COVID-19. Overall, the treatment with anti-Th2 biologics can be considered safe during COVID-19. It does not worsen the clinical course and outcome of COVID-19, and it may be actually protective somehow from developing severe forms. Moreover, patients treated with these biological agents do not seem to be more prone to get infected by SARS-CoV-2.

show abstract

“…Again, only one case of COVID-19 at week-10 was mentioned, and this is supposed to be the same reported in the previous article. 43 …”

Section: Dupilumabmentioning

confidence: 99%

mentioning

confidence: 91%

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Poddighe¹,

Kovzel²

2021

JIR

View full text Add to dashboard Cite

show abstract

“…Our real-life experience confirms data reported in literature about effectiveness of dupilumab in adolescent. [7][8][9] We observed a marked reduction in the median values of pruritus assessed by SCORAD and ppNRS, in association with an improvement of skin involvement. The decrease of pruritus recorded at week 4 was slightly lower than the one we had detected in adult patients (37.5 vs. 50%) in a much larger cohort.…”

mentioning

confidence: 56%

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study

Mastorino

Viola

Panzone

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

“…The first drug approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe AD was dupilumab in December 2020. Dupilumab is approved for adolescents with moderate to severe AD eligible for systemic therapy and can currently be considered as a first-choice systemic treatment in this population [10,11].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

Sidbury

Alpizar²,

Laquer

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Nemolizumab, a new monoclonal antibody that targets the receptor alpha of the neuroimmune cytokine interleukin-31 (IL-31), has shown efficacy in atopic dermatitis (AD) in adults. This study evaluated the pharmacokinetics (PK) and safety of nemolizumab in adolescents with moderate to severe AD as well as the relationship between nemolizumab concentrations and clinical efficacy and the effect of nemolizumab on protein biomarkers. Methods: Open-label, 16-week study of nemolizumab in patients aged 12-17 years with moderate to severe AD (baseline EASI C 16, IGA C 3, and BSA C 10%) and associated pruritus with baseline average daily peak pruritus numeric rating scale (PP-NRS) intensity of at least 4. Nemolizumab was administered subcutaneously as a loading dose of 60 mg at baseline, followed by 30 mg every 4 weeks until week 12 with background topical corticosteroids (TCS) or calcineurin inhibitors (TCI). Subsequently patients were followed for 8 weeks more. Stratum corneum (SC) and plasma samples were collected for biomarker assessments. Results: Twenty patients participated, with a mean age of 14.8 ± 1.6 years. The PK of nemolizumab was described by a one-compartment model with linear elimination, a first-order absorption, and a mean half-life of 16.7 ± 4.1 days. Mean trough concentrations ranged from 2935 ± 1029 ng/mL to 3292 ± 2018 ng/mL over the 16-week treatment period.

show abstract

Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

Cited by 25 publications

References 5 publications

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

Contact Info

Product

Resources

About